Parkinson disease therapeutic agents

Neurotensin agonists that cross the blood-brain barrier have been developed and have potential as potential therapeutic agents for diseases such as schizophrenia and Parkinson s disease (McMahon,... 

In this section, we describe as typical examples the application of (R)-PGA as a chiral vehicle in the preparation of (5)-l-aminoindane3s (see also Chapter 24) and (,S )-3,3-dimethyl-2-butylamine. (S)-l-Aminoindane is present as a key structural element (or with additional functionalization) in therapeutic agents under clinical investigation [e.g., Rasagiline mesylate, (18) for the treatment of Parkinson s disease,39 and Irindalone (19), which displays potent antihypertensive activity].40... 

Later, the disease does not respond to the drug and doses are required to be given in combination with carbidopa. Levodopa is effective in relieving bradykinesia and other disorderly voluntary movements. Parkinson s disease is not a hereditary disease. Drugs such as levodopa, carbidopa, benserazide, bromocriptine, pergolide, selegiline, and amantadine are used as therapeutic agents.61... 

Dopamine biosynthesis is diminished in Parkinson s disease. L-Dopa, a precursor of dopamine, is given in large doses as a therapeutic agent. 

Bonifati V, Meco G. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson s disease. Pharmacol. Ther. 1999 8 1-36. 

Hamilton, G.S. (1998) Emerging therapeutic agents for Parkinson s disease. Chemistry and Industry 127-132. 

The possibility of increasingly efficacious muscarinic therapeutic agents greatly depends on a sound knowledge of the functional role of the multiple muscarinic receptors expressed in the brain and in the periphery. In fact, many diseases including Alzheimer and Parkinson s, urinary incontinence, irritable bowel syndrome, and chronic obstruc-... 

The ability of conotoxins to selectively block ion channels and neuronal receptors has led to their development into therapeutic agents. So far, most conotoxin applications as therapeutics have been concentrated on the treatment of different forms of pain. The first drug of marine origin is based on the w-conotoxin MVIIA for the treatment of chronic pain (see helow). Other therapeutic applications of conotoxins include treatment of schizophrenia, epilepsy, neuromuscular disorders, certain types of cancer, urinary dysfunction, Parkinson s disease, Alzheimer s disease, stroke, and related hrain injuries. Other uses include muscle relaxants, anesthetics, and antiseizure compounds. As the demand for new painkillers and other neuropharmacological agents is expected to increase, the value of the discovery and testing of new conotoxins is expected to continue to expand. 

---